ArticleGenome biology and evolution2026
Emergence and Tandem Repeat-Mediated Elongation of a Translated De Novo Open Reading Frame in Human Oncogenic RNA Gene VPS9D1-AS1 (MYU).
Article in Genome biology and evolution, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
New protein-coding genes can arise de novo from ancestrally noncoding regions when open reading frames (ORFs) outside existing genes are exposed to selection via pervasive translation. These ORFs are usually born short, and their elongation is considered a key step in de novo gene birth. However, mechanisms of de novo gene elongation remain understudied. Here, we reconstructed the evolutionary history of c16riboseqorf143 (orf143), one of the longest unannotated human translated ORFs. orf143 is encoded in the oncogenic long noncoding RNA (lncRNA) VPS9D1-AS1 (MYU). Evolutionary reconstruction showed that orf143 originated de novo in the common ancestor of simians through a point mutation that introduced a start codon. A subsequent stop-codon-disrupting mutation extended translation into a downstream region that, in humans, includes multiple binding sites and a tandem repeat (TR) array previously reported to mediate the oncogenicity of VPS9D1-AS1. The TR array frequently expanded in human populations. The overlaps between orf143 and the oncogenic binding sites in VPS9D1-AS1 raise the possibility that orf143 translation may be tumor-suppressive, since ribosomes may compete with oncogenic binding events via steric hindrance. In line with this possibility, we observed an enrichment of somatic mutations in the ORF regions of VPS9D1-AS1 in cancer patients and a positive association between in-ORF mutations and adenomas/adenocarcinomas. Some of these mutations induced truncation of the ORF, potentially impairing ribosome binding to VPS9D1-AS1. This study reveals stop codon disruption and TR array expansion as the mechanisms of orf143 elongation and illustrates how elongation of de novo ORFs may provide a selective advantage.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.